SCHEMBL1971145

SCHEMBL1971145

CC(C)(C)C1[C@H](c2ccc(Cl)c(Cl)c2)[C@H](N2CCN(c3ccccc3)C2=O)CCN1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.35
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
SLC6A9 P48067 1/20 0.33
SLC6A5 Q9Y345 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
F2 P00734 1/20 0.33
F10 P00742 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1969505 0.82 HSD11B1 (0.35) PDE5ASLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL1971062 0.79 TACR1 (0.41)
SCHEMBL15397491 0.77 SLC6A9 (0.41) MEN1KMT2ASLC6A9SLC6A5NPC1
SCHEMBL1971567 0.76 TACR1 (0.40) KCNH2
SCHEMBL1971144 0.75 USP30 (0.51) MEN1KMT2A
SCHEMBL1969398 0.72 LMNA (0.37) MEN1KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL1973883 0.72 TACR1 (0.56)
SCHEMBL1971001 0.71 SLC6A4 (0.37) PDE5AMEN1KMT2ASLC6A2SLC6A4
SCHEMBL1968593 0.70 TACR2 (0.38) PDE5ATSHRSLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL1971017 0.69 SLC6A9 (0.43) SLC6A9SLC6A5SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
EP-2336105-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B PDE5A 3436/4885MEN1 209/4885KMT2A 1146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.